MedPage Today

FDA Advisers Reject Nuplazid for Alzheimer's Disease Psychosis

A US Food and Drug Administration advisory panel has rejected the atypical antipsychotic pimavanserin for the treatment of Alzheimer's disease psychosis. In a 9-3 vote, the Psychopharmacologic Drugs Advisory Committee found that the drug's manufacturer failed to offer convincing evidence of its efficacy in patients with ADP. "I do also have concerns that once medications or treatments are made available for problems like this ... it's a little like the genie being let out of the bottle," said Paul Stander, MD, clinical assistant professor with the University of Arizona College of Medicine – Phoenix, who voted against recommending approval.

About the College

Founded in 2007, the University of Arizona College of Medicine – Phoenix inspires and trains exemplary physicians, scientists and leaders to optimize health and health care in Arizona and beyond. By cultivating collaborative research locally and globally, the college accelerates discovery in a number of critical areas — including cancer, stroke, traumatic brain injury and cardiovascular disease. Championed as a student-centric campus, the college has graduated 669 physicians, all of whom received exceptional training from nine clinical partners and more than 2,600 diverse faculty members. As the anchor to the Phoenix Bioscience Core, which is projected to have an economic impact of $3.1 billion by 2025, the college prides itself on engaging with the community, fostering education, inclusion, access and advocacy.